Vanguard Group Inc. Has $29.96 Million Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)

Vanguard Group Inc. raised its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) by 14.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,968,108 shares of the company’s stock after acquiring an additional 246,596 shares during the period. Vanguard Group Inc.’s holdings in Cabaletta Bio were worth $29,955,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in CABA. Citigroup Inc. boosted its stake in Cabaletta Bio by 552.4% in the 3rd quarter. Citigroup Inc. now owns 49,695 shares of the company’s stock valued at $756,000 after purchasing an additional 42,078 shares during the period. Wellington Management Group LLP acquired a new stake in shares of Cabaletta Bio during the third quarter worth $3,753,000. Deutsche Bank AG boosted its position in shares of Cabaletta Bio by 84.7% in the third quarter. Deutsche Bank AG now owns 21,135 shares of the company’s stock valued at $322,000 after acquiring an additional 9,692 shares during the period. Comerica Bank acquired a new position in shares of Cabaletta Bio in the third quarter valued at about $31,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Cabaletta Bio by 26.3% in the third quarter. The Manufacturers Life Insurance Company now owns 13,250 shares of the company’s stock valued at $202,000 after acquiring an additional 2,761 shares in the last quarter.

Wall Street Analyst Weigh In

CABA has been the subject of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $50.00 price objective on shares of Cabaletta Bio in a report on Friday, April 5th. Jefferies Financial Group started coverage on Cabaletta Bio in a research note on Monday, February 5th. They issued a “buy” rating and a $36.00 price target for the company. HC Wainwright raised their price objective on Cabaletta Bio from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Citigroup upped their target price on Cabaletta Bio from $26.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, April 4th. Finally, Wells Fargo & Company raised their price target on Cabaletta Bio from $34.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, March 22nd. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $34.33.

Insider Transactions at Cabaletta Bio

In related news, insider Gwendolyn Binder sold 11,000 shares of Cabaletta Bio stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $19.59, for a total transaction of $215,490.00. Following the sale, the insider now directly owns 20,000 shares of the company’s stock, valued at approximately $391,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 12.33% of the company’s stock.

Cabaletta Bio Stock Up 0.3 %

NASDAQ:CABA opened at $17.91 on Friday. Cabaletta Bio, Inc. has a twelve month low of $7.69 and a twelve month high of $26.35. The stock’s 50-day simple moving average is $20.59 and its 200 day simple moving average is $18.91. The firm has a market capitalization of $864.01 million, a PE ratio of -10.85 and a beta of 2.41.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.